Claims
- 1. A replaceable matrix formulation comprising:
(a) a linear polyacrylamide solution; (b) at least one denaturant; (c) a buffer; and (d) 6M urea.
- 2. The matrix formulation according to claim 1, wherein the linear polyacrylamide concentration is at least 1% (w/w).
- 3. The matrix formulation according to claim 2, wherein the linear polyacrylamide concentration ranges between 1%-3% (w/w).
- 4. The matrix formulation according to claim 1, wherein the denaturant is organic.
- 5. The matrix formulation according to claim 4, wherein the organic denaturant is selected from the group consisting of:
(a) 2-pyrrolidinone; (b) N′,N′-dimethylacetamide; and (c) N′,N′-dimethylformamide.
- 6. The matrix formulation according to claim 4, wherein the organic denaturant concentration ranges between 5%-20% (w/w).
- 7. The matrix formulation according to claim 5, wherein the organic denaturant is 2-pyrrolidinone.
- 8. A method of biomacromolecule separation using a capillary electrophoresis device comprising the matrix formulation according to claim 1 and a buffer.
- 9. The method according to claim 8, wherein the electrophoresis device is operated at a run voltage of between 10 kV-12 kV.
- 10. The method according to claim 8, wherein the electrophoresis device is operated at a run voltage of at least 12 kV.
- 11. The method according to claim 8, wherein the electrophoresis device is operated at temperature ranging between 40° C. and 60° C.
- 12. The method according to claim 11, wherein the electrophoresis device is operated at 44° C.
- 13. The method according to claim 8, wherein the buffer consists essentially of:
(a) EDTA, with a concentration ranging between 0.6-1.0 MM; (b) Trizma Base, with a concentration ranging between 12-30 mM; and (c) TAPS, with a concentration ranging between 50-85 mM.
- 14. The method according to claim 8, wherein the biomacromolecule separation is used in nucleic acid sequencing.
- 15. The method according to claim 8, wherein the biomacromolecule separation is used in the determination of the molecular size of a biomacromolecule.
- 16. The method according to claim 8, wherein the biomacromolecule separation is used in the differential display of mRNA.
- 17. The method according to claim 8, wherein the biomacromolecule separation is used in dideoxyfingerprinting.
- 18. The method according to claim 8, wherein the biomacromolecule separation is used in STR analysis.
RELATED PATENT APPLICATIONS
[0001] The instant application claims the benefit under 35 U.S.C. §119(e) to United States provisional application Serial No. 60/107,798, filed on Nov. 10, 1998.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60107798 |
Nov 1998 |
US |